Literature DB >> 16195917

Extensive cortico-subcortical lesions in Wilson's disease: clinico-pathological study of two cases.

Jacqueline Mikol1, Claude Vital, Michel Wassef, Philippe Chappuis, Joël Poupon, Monique Lecharpentier, France Woimant.   

Abstract

Wilson's disease (WD) with extensive cortico-subcortical lesions represents a rare neuropathological subgroup, the pathogenesis of which is not clearly determined. We report two new cases with identical lesions. In the families of each of the patient, there were mutations in the ATPase7B gene, especially in the family of proband 1, and in the first cousin of proband 2. These cases included massive destruction of the white matter in superior gyri, mostly frontal, extending to the deep cortex with neuronal loss and capillary proliferation. Astrocytes were of Alzheimer type 1 and 2; and type 1 were labeled by anti-metallothionein. Opalski cells were abundant and their macrophagic lineage was confirmed by immunostaining. Among the possible mechanisms proposed, the role of vascular factors and penicillamine treatment could be excluded. Cerebral copper content in white matter and putamen of case 1 was at the same level as in common WD but accumulation of unbound copper in the white matter was a distinctive feature, which suggested a pathological neurotoxic effect.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16195917     DOI: 10.1007/s00401-005-1061-1

Source DB:  PubMed          Journal:  Acta Neuropathol        ISSN: 0001-6322            Impact factor:   17.088


  11 in total

Review 1.  Challenges in the diagnosis of Wilson disease.

Authors:  Aurélia Poujois; France Woimant
Journal:  Ann Transl Med       Date:  2019-04

Review 2.  Neurologic impairment in Wilson disease.

Authors:  Petr Dusek; Tomasz Litwin; Anna Członkowska
Journal:  Ann Transl Med       Date:  2019-04

Review 3.  Clinico-radiological spectrum of bilateral temporal lobe hyperintensity: a retrospective review.

Authors:  J Sureka; R K Jakkani
Journal:  Br J Radiol       Date:  2012-03-14       Impact factor: 3.039

4.  Up-regulation of metallothionein gene expression in parkinsonian astrocytes.

Authors:  Gregory J Michael; Sharmin Esmailzadeh; Linda B Moran; Lynne Christian; Ronald K B Pearce; Manuel B Graeber
Journal:  Neurogenetics       Date:  2011-07-29       Impact factor: 2.660

Review 5.  Wilson disease.

Authors:  Anna Członkowska; Tomasz Litwin; Petr Dusek; Peter Ferenci; Svetlana Lutsenko; Valentina Medici; Janusz K Rybakowski; Karl Heinz Weiss; Michael L Schilsky
Journal:  Nat Rev Dis Primers       Date:  2018-09-06       Impact factor: 52.329

6.  Wilson's disease: two treatment modalities. Correlations to pretreatment and posttreatment brain MRI.

Authors:  Maria do Desterro Leiros da Costa; Mariana Spitz; Luiz Alberto Bacheschi; Claudia Costa Leite; Leandro Tavares Lucato; Egberto Reis Barbosa
Journal:  Neuroradiology       Date:  2009-05-29       Impact factor: 2.804

7.  Higher Concentration of Plasma Glial Fibrillary Acidic Protein in Wilson Disease Patients with Neurological Manifestations.

Authors:  Jie Lin; Yexiang Zheng; Ying Liu; Yi Lin; Qiqi Wang; Xiao-Hong Lin; Wenli Zhu; Wei-Hong Lin; Ning Wang; Wan-Jin Chen; Ying Fu
Journal:  Mov Disord       Date:  2021-01-27       Impact factor: 10.338

8.  Social cognition in Wilson's disease: A new phenotype?

Authors:  Elodie Peyroux; Nelly Santaella; Emmanuel Broussolle; Caroline Rigard; Emilie Favre; Anne-Sophie Brunet; Muriel Bost; Alain Lachaux; Caroline Demily
Journal:  PLoS One       Date:  2017-04-06       Impact factor: 3.240

9.  Basal ganglia-orbitofrontal circuits are associated with prospective memory deficits in Wilson's disease.

Authors:  Sheng Hu; ChunSheng Xu; Yi Wang; Ting Dong; Hongli Wu; Anqin Wang; Chuanfu Li; BenSheng Qiu
Journal:  Brain Imaging Behav       Date:  2021-07-23       Impact factor: 3.978

10.  Unusual epileptic deterioration and extensive white matter lesion during treatment in Wilson's disease.

Authors:  Young Eun Kim; Ji Young Yun; Hui-Jun Yang; Han-Joon Kim; Beom S Jeon
Journal:  BMC Neurol       Date:  2013-09-25       Impact factor: 2.474

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.